MoneyWorks4Me

Sakar Healthcare - Quaterly Results

15 May 2025 Evaluate
The revenue for the March 2025 quarter is pegged at Rs. 502.42 millions, about 16.68% up against Rs. 430.59 millions recorded during the year-ago period.Profit after tax for the quarter ended March 2025 reported a huge growth of 84.62% to Rs. 57.62  millions from Rs. 31.21 millions.Operating Profit saw a handsome growth to 159.07 millions from 117.37 millions in the quarter ended March 2025.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202503 202403 % Var 202503 202403 % Var 202503 202403 % Var
Sales 502.42 430.59 16.68 1775.85 1533.52 15.80 1775.85 1533.52 15.80
Other Income 1.82 7.68 -76.30 13.13 31.77 -58.67 13.13 31.77 -58.67
PBIDT 159.07 117.37 35.53 509.96 415.41 22.76 509.96 415.41 22.76
Interest 41.93 20.76 101.97 85.35 75.90 12.45 85.35 75.90 12.45
PBDT 117.14 96.61 21.25 424.10 339.51 24.92 424.10 339.51 24.92
Depreciation 54.77 48.66 12.56 208.82 180.50 15.69 208.82 180.50 15.69
PBT 62.37 47.95 30.07 215.28 159.01 35.39 215.28 159.01 35.39
TAX 4.75 16.74 -71.62 40.25 42.29 -4.82 40.25 42.29 -4.82
Deferred Tax 4.75 16.74 -71.62 40.25 42.29 -4.82 40.25 42.29 -4.82
PAT 57.62 31.21 84.62 175.03 116.72 49.96 175.03 116.72 49.96
Equity 219.50 217.50 0.92 219.50 217.50 0.92 219.50 217.50 0.92
PBIDTM(%) 31.66 27.26 16.15 28.72 27.09 6.01 28.72 27.09 6.01
Peers
Company Name CMP
Sun Pharma. Inds. 1864.00
Dr. Reddys Labs. 1140.80
Cipla 1380.00
Lupin 2075.00
Zydus Lifesciences 1118.00
View more..